Luke Maese
No Rating Available
(Learn About Our Rating System)

Luke Maese, DO

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-4700
Get Directions

  • Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

    Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise and co-Director of the Bone Marrow Failure program within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

    Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trial development in pediatric acute lymphoblastic leukemia. He is a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

    For questions regarding Dr. Maese's family cancer assessment clinic practice at the Huntsman Cancer Institute please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-9555 or go to Family History of Cancer | Huntsman Cancer Institute | University of Utah Health for more information.

    For questions regarding Dr. Maese's pediatric practice and the Leukemia/Lymphoma Program at Primary Children's Medical Center, please call (801) 662-4700.

    Specialties

    Board Certification

    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

    Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise and co-Director of the Bone Marrow Failure program within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

    Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trial development in pediatric acute lymphoblastic leukemia. He is a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

    For questions regarding Dr. Maese's family cancer assessment clinic practice at the Huntsman Cancer Institute please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-9555 or go to Family History of Cancer | Huntsman Cancer Institute | University of Utah Health for more information.

    For questions regarding Dr. Maese's pediatric practice and the Leukemia/Lymphoma Program at Primary Children's Medical Center, please call (801) 662-4700.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Associate Professor (Clinical)
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Undergraduate Human Biology - University of Kansas B.G.S.
    Professional Medical Osteopathic Medicine - Kansas City University of Medicine and Biosciences D.O.
    Residency Pediatrics - Children¿s Hospital of Pittsburgh of UPMC Resident
    Fellowship Pediatric Hematology/Oncology - University of Utah Fellow

    Selected Publications

    Journal Article

    1. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey A (2022). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clinical neurology and neurosurgery, 212, 107064.
    2. Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard C (2021). Inherited TP53 Variants and Risk of Prostate Cancer. European urology,
    3. Hecht A, Meyer JA, Behnert A, Wong E, Chehab F, Olshen A, Hechmer A, Aftandilian C, Bhat R, Choi SW, Chonat S, Farrar JE, Fluchel M, Frangoul H, Han JH, Kolb EA, Kuo DJ, MacMillan ML, Maese L, Maloney KW, Narendran A, Oshrine B, Schultz KR, Sulis ML, Van Mater D, Tasian SK, Hofmann WK, Loh ML, Stieglitz (2020). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, Online ahead of print, 178-186. (Read full publication)
    4. Hamilton KV, Maese L, Marron JM, Pulsipher MA, Porter CC, Nichols K (2019). Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?. Journal of clinical oncology, 37(24), 2098-2104. (Read full publication)
    5. Iglesias Cardenas F, Agarwal AM, Vagher J, Maese L, Fluchel M, Afify (2021). Two Clonally Distinct B-Cell Lymphomas Reveal the Diagnosis of XLP1 in a Male Child and His Asymptomatic Male Relatives: Case Report and Review of the Literature. Journal of pediatric hematology/oncology, 43(8), e1210-e1213. (Read full publication)
    6. Maese L, Raetz E (2019). Can Ph-like ALL be effectively targeted?. Best practice & research. Clinical haematology, 32(4), 101096. (Read full publication)
    7. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman J (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatric blood & cancer, 66(5), e27629. (Read full publication)
    8. Lozano-Chinga M*, Draper L, George TI, Agarwal AM, Dansie DM, Maese (2021). Bone marrow necrosis in pediatric malignancies: 10-Year retrospective review and review of literature. Pediatric blood & cancer, 68(3), e28806. (Read full publication)
    9. Maese L, Rizzari C, Coleman R, Power A, van der Sluis I, Rau R (2021). Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?. Pediatric blood & cancer, 68(10), e29169. (Read full publication)
    10. Maese L, Li KD, Xu X, Afify Z, Paxton CN, Putnam (2017). Acute Leukemia and Concurrent Mediastinal Germ Cell Tumor: Case Report and Literature Review. Fetal and pediatric pathology, 36(2), 168-176. (Read full publication)
    11. Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba (2020). Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(1), 81-112. (Read full publication)
    12. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance J (2021). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. Journal of adolescent and young adult oncology, 10(2), 175-184. (Read full publication)
    13. Hendrickson PG, Luo Y, Kohlmann W, Schiffman J, Maese L, Bishop AJ, Lloyd S, Kokeny KE, Hitchcock YJ, Poppe MM, Gaffney DK, Tao (2020). Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer medicine, 9(21), 7954-7963. (Read full publication)
    14. Olson J, Mehra S, Hersh AL, Thorell EA, Stoddard GJ, Maese L, Barnette PE, Lemons RS, Pavia AT, Knackstedt E (2021). Oral Step-Down Therapy With Levofloxacin for Febrile Neutropenia in Children With Cancer. Journal of the Pediatric Infectious Diseases Society, 10(1), 27-33. (Read full publication)
    15. Bender C, Maese L, Carter-Febres M, Verma (2021). Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood and lymphatic cancer, 11, 25-40. (Read full publication)
    16. Mangum DS, Meyer JA, Mason CC, Shams S, Maese LD, Gardiner JD, Downie JM, Pei D, Cheng C, Gleason A, Luo M, Pui CH, Aplenc R, Hunger SP, Loh M, Greaves M, Trede N, Raetz E, Frazer JK, Mullighan CG, Engel ME, Miles RR, Rabin KR, Schiffman J (2021). Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA oncology, 7(10), 1521-1528. (Read full publication)
    17. Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart D (2021). Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. JCO precision oncology, 5, (Read full publication)
    18. Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox (2022). Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations (STARTRK-NG). Neuro-oncology, 24(10), 1776-1789. (Read full publication)
    19. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara (2021). Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO precision oncology, 5, (Read full publication)
    20. Maese LD, Loh ML, Choi MR, Lin T, Aoki E, Zanette M, Agarwal S, Iannone R, Silverman JA, Silverman LB, Raetz EA, Rau R (2023). Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. . Blood, 141(7), 704-712. (Read full publication)
    21. MacFarland SP, Maese L, Rednam SP, Kamihara J, Perrino MR, Nichols KE, Brodeur GM, Schiffman JD, Plon SE, Diller LR, Malkin D, Porter CC, Villani (2022). Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer prevention research (Philadelphia, Pa.), 15(10), OF1-OF7. (Read full publication)
    22. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway K (2022). Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature medicine, 28(8), 1581-1589. (Read full publication)
    23. Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest S (2022). Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO precision oncology, 6, e2200390. (Read full publication)
    24. Fair D, Maese L, Chi YY, Li M, Hawkins DS, Venkatramani R, Rudzinski E, Parham D, Teot L, Malkin D, Plon SE, Li H, Sabo A, Lupo PJ, Schiffman J (2023). TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. Pediatric blood & cancer, e30413. (Read full publication)
    25. Foley M, Sharma A, Garfield K, Maese L, Buchmann L, Boyle J, Kohlmann W, Jeter J, Greenberg (2023). A need to tailor surveillance based on family history: describing a highly penetrant familial paraganglioma kindred with an SDHD pathogenic variant. Familial cancer, 22(2), 217-224. (Read full publication)
    26. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway K (2023). Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO precision oncology, 7, e2200334. (Read full publication)
    27. Beigh M, Vagher J, Codden R, Maese LD, Cook S, Gammon (2024). Newborn Screening for Li-Fraumeni Syndrome: Patient Perspectives. Research square, (Read full publication)
    28. Maese LD, Wlodarski MW, Kim SY, Bertuch AA, Bougeard G, Chang VY, Godley LA, Khincha PP, Kuiper RP, Lesmana H, McGee RB, McReynolds LJ, Meade J, Plon SE, Savage SA, Scollon SR, Scott HS, Walsh MF, Nichols KE, Porter C (2024). Update on Recommendations for Surveillance for Children with Predisposition to Hematopoietic Malignancy. Clinical cancer research, (Read full publication)
    29. Nakano Y, Kuiper RP, Nichols KE, Porter CC, Lesmana H, Meade J, Kratz CP, Godley LA, Maese LD, Achatz MI, Khincha PP, Savage SA, Doria AS, Greer MC, Chang VY, Wang LL, Plon SE, Walsh M (2024). Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders. Clinical cancer research, 30(22), 5009-5020. (Read full publication)
    30. Maese LD, Loh ML, Choi MR, Agarwal S, Aoki E, Liang Y, Lin T, Girgis S, Chen C, Roller SG, Chandrasekaran V, Iannone R, Silverman LB, Raetz EA, Rau R (2024). Recombinant Erwinia Asparaginase (JZP458) in ALL/LBL: Complete Follow-Up of the Children's Oncology Group AALL1931 Study. Blood advances, (Read full publication)
    31. Fan EM*, Vagher J, Meznarich JA, Ubico EM, Goteti S, Peterson D, Rayes A, Maese L (2023). Severe congenital neutropenia, SRP54 pathogenicity, and a framework for surveillance. American journal of medical genetics. Part A, 191(5), 1434-1441. (Read full publication)
    32. Achatz MI, Villani A, Bertuch AA, Bougeard G, Chang VY, Doria AS, Gallinger B, Godley LA, Greer MC, Kamihara J, Khincha PP, Kohlmann WK, Kratz CP, MacFarland SP, Maese LD, Maxwell KN, Mitchell SG, Nakano Y, Pfister SM, Wasserman JD, Woodward ER, Garber JE, Malkin (2025). Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical cancer research, (Read full publication)
    33. Sharma R, Zhang C, Shah R, Frigault MM, Johnson AJ, Mangum DS, Maese LD, Lacayo NJ, Narendran (2025). Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. Blood neoplasia, 2(4), 100148. (Read full publication)
    34. Aldoss I, Ali A, Cassaday RD, Curran EK, Luskin MR, Maese LD, Orgel E, Douer (2025). Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations. American journal of hematology, (Read full publication)
    35. Moses R, Indeglia A, Levine AS, Hausler R, Kelly G, Miller SA, Anez I, Heller M, Delgado R, Orr C, Kohlmann W, Naumer A, Vagher J, Cahill SR, Maese LD, Karanicolas J, Garber JE, Murphy ME, Maxwell K (2025). Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis. bioRxiv, (Read full publication)
    36. Sleiman MM Jr, Statman MR, Yockel MR, Wu YP, Hamilton JG, Kohlmann WK, Vagher J, Feola S, Maese LD, Chen J, Appel B, Mehrhoff CJ, Peshkin BN, Kadan-Lottick NS, Kupfer GM, Tercyak K (2025). Parental perspectives on the use of tumor molecular profiling and germline genetic testing during their children's cancer treatment. Familial cancer, 24(3), 63. (Read full publication)
    37. Vagher J, Zakas A, Donovan L, Shoger K, Naumer A, Bly J, Smith-Simmer K, Maese L, Schiffman J, Kohlmann W, Garzon R, Churpek JE, Osman AE (2025). Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome. JCO precision oncology, 9, e2400860. (Read full publication)
    38. Fernandes CJ, Du YK, Naumer A, Kagami LA, Le A, Good M, Duvall M, Powers J, Zelley K, Maese LD, MacFarland S, Kohlmann W, Maxwell KN, Katona B (2025). Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome. Pancreas, 54(7), e618-e623. (Read full publication)
    39. Mathis CL, Meeks HD, Watt KM, Maese LD, Constance J (2025). Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and Young Adults with Cancer. (Read full publication)
    40. Kamihara J, Fisher L, Schienda J, Vanderwall R, Snir M, Snir G, Simmons E, Khalaj A, Goler E, Hamilton KV, Porter CC, Pencheva B, Schiffman JD, Maese LD, Kohlmann W, Henderson TO, Garber JE, Diller LR, Desai AV, Savage S, Klosky JL, Rana HQ, Mack J (2026). Development and pilot testing of AYA-RISE, a risk information and screening education intervention for adolescents and young adults with cancer risk syndromes. Familial cancer, 25(1), 11. (Read full publication)
    41. Kang W, Lazo de la Vega L, Comeau H, Agastra E, Maese LD, Kim A, Sukharevsky E, Ceca E, Corson L, White J, Weiser DA, Applebaum MA, Colace SI, Chen M, Johnson JA, Volchenboum S, Pinto NR, Church AJ, Janeway K (2026). Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies. Communications medicine, 6(1), 88. (Read full publication)
    42. Mathis CL, Meeks HD, Watt KM, Maese LD, Constance J (2025). Acetaminophen and Acetaminophen-Opioid Combination Prescribing Trends Among Hospitalized Children, Adolescents, and Young Adults with Cancer. Pharmacological research. Reports, 4, (Read full publication)

    Review

    1. Maese L, Rau R (2022). Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Frontiers in pediatrics, 10, 902117. (Read full publication)
    2. Maese LD, Pulsipher M (2023). Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL. Journal of clinical oncology, 41(25), 4087-4092. (Read full publication)
    3. Vagher J,Dietz MS,Schiffman JD,Kohlmann W,Maese (2022). Germline predisposition to soft tissue sarcoma. Journal of cancer metastasis and treatment, 8, (Read full publication)
    4. Vagher J, Mehrhoff CJ*, Florou V, Maese L (2024). Genetic Predisposition to Sarcoma: What Should Clinicians Know?. Current treatment options in oncology, 25(6), 769-783. (Read full publication)

    Letter

    1. Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. British journal of haematology, 198(6), e78-e81. (Read full publication)

Schedule Online